Online Purchasing Account You are logged on as Guest. Login Register a New Account Shopping cart (Empty)

8-CPT-cAMP

PKA activator



BML-CN130-0020	20 mg	83.00 USD

BML-CN130-0100	100 mg	338.00 USD
Do you need bulk/larger quantities?

Replaces Prod. #: ALX-480-030

A lipophilic, cell-permeable cAMP analog which activates cAMP- and cGMP-dependent protein kinase. More potent than cAMP and more resistant to phosphodiesterasese, with good selectivity for site B of PKA. For specific activation of the cAMP pathway the highly membrane permeable Sp-5,6-DCI-cBIMPS (Prod. No. BML-CN135).

Product Details

Formula:	C₁₆H₁₄CIN₅O₆PS . Na

MW:	493.8

Source:	Synthetic.

CAS:	93882-12-3

Purity:	≥96% (HPLC)

Appearance:	White solid.

Solubility:	Soluble in water (25mg/ml).

Shipping:	Ambient

Long Term Storage:	-20°C

Use/Stability:	Store as supplied (solid) at -20°C for 1 year. Once dissolved in water, it can be stored frozen at -20°C up to 3 months.

Regulatory Status:	RUO - Research Use Only

Please mouse over

Product Literature References

Serum- and glucocorticoid-induced kinase drives hepatic insulin resistance by directly inhibiting AMP-activated protein kinase: B. Zhou, et al.; Cell Rep. 37, 109785 (2021), Abstract;

The nuclear bile acid receptor FXR is a PKA- and FOXA2-sensitive activator of fasting hepatic gluconeogenesis: M. Ploton, et al.; J. Hepatol. 69, 1099 (2018), Abstract;

Glucagon-like peptide-1 Regulates Cholecystokinin Production in β-cells to Protect from Apoptosis: A.K. Linnemann, et al.; Mol. Endocrinol. 29, 978 (2015), Application(s): Cell Culture, Abstract; Full Text

Cyclic nucleotide phosphodiesterase 1 regulates lysosome-dependent type I collagen protein degradation in vascular smooth muscle cells: Y. Cay, et al.; Arterioscler. Thromb. Vasc. Biol. 31, 616 (2011), Abstract; Full Text

The role of protein kinase A anchoring via the RII alpha regulatory subunit in the murine immune system: R.V. Schillace et al.; J. Immunol. 174, 6847 (2005), Abstract;

8-(4-Chlorophenyl)thio-cyclic AMP is a potent inhibitor of the cyclic GMP-specific phosphodiesterase (PDE VA): B.J. Connolly et al.; Biochem. Pharmacol. 44, 2303 (1992), Abstract;

Role of cGMP and cGMP-dependent protein kinase in nitrovasodilator inhibition of agonist-evoked calcium elevation in human platelets: J. Geiger et al.; PNAS 89, 1031 (1992), Abstract;

Characterization of Sp-5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole- 3',5'-monophosphorothioate (Sp-5,6-DCl-cBiMPS) as a potent and specific activator of cyclic-AMP-dependent protein kinase in cell extracts and intact cells: M. Sandberg et al; Biochem. J. 279 , 521 (1991), Abstract;

Stoichiometric and reversible phosphorylation of a 46-kDa protein in human platelets in response to cGMP- and cAMP-elevating vasodilators: M. Halbrugge et al.; J. Biol. Chem. 265, 3088 (1990), Abstract;

Comparison of the two classes of binding sites (A and B) of type I and type II cyclic-AMP-dependent protein kinases by using cyclic nucleotide analogs: D. Ogreid et al.; Eur. J. Biochem. 181, 19 (1989), Abstract;

cAMP analogs promote survival and neurite outgrowth in cultures of rat sympathetic and sensory neurons independently of nerve growth factor: R.E. Rydel & L.A. Greene; PNAS 85, 1257 (1988), Abstract;